MarketWatch

Glaxo's Seretide improves lung-disease patient survival: study

LONDON (MarketWatch) -- Lung-disease patients taking GlaxoSmithKline PLC's GSK asthma inhaler Seretide have better survival benefits than those taking a rival product, according to a study published ...
FiercePharma

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Reuters

Glaxo's Seretide approved for wider use in Europe

LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
FiercePharma

Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler® (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla ...

Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy ...
Medscape

Short-Term Safety and Tolerability of Double-Dose Salmeterol/Fluticasone Propionate in Adult Asthmatic Patients

This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...